Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xtent in phase II trial for customisable DES (drug-eluting stent)

This article was originally published in Clinica

Executive Summary

The Menlo, Park, California company, Xtent, has begun enrolling up to 100 patients in its CUSTOM II trial of a modular drug-eluting stent (DES) system that allows cardiologists to customise the stent length to match the patient's lesion. After deployment of the sheath-covered Xtent system, the cardiologist decides how many of the 4mm segments are needed to span the target lesion, retracts the sheath, detaches the correct length stent and then expands the stent with the integrated balloon.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058108

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel